News
Displaying 41–50 of 576
-
Beacon Therapeutics Launches Clinical Trial for Bilateral Administration of XLRP Gene Therapy
Research NewsThe company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
-
SparingVision Launches Clinical Trial for Therapy to Re-Activate Dormant Cones in Advanced RP
Research NewsThe approach may provide better visual acuity than current optogenetic therapies in clinical trials.
-
Annual Funded Grants – CRISPR and Prime Editing Technologies
Research NewsFunded grants for CRISPR and prime editing approaches.
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Foundation Fighting Blindness Celebrates Blindness Awareness Month with #ShareYourVision Campaign
Foundation NewsThis social media campaign amplifies authentic stories from the blind and low vision community to highlight the spectrum of vision loss experiences.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
.png)
